Trials / Completed
CompletedNCT03616769
A Prospective Cohort Study of China Serum Uric Acid Levels
Relationship of Serum Uric Acid Levels With All Cause Mortality and Cardiovascular Mortality in Multiple Classical Framingham Risk Factors Patients After a Six-year Follow-up: a China Prospective Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,535 (actual)
- Sponsor
- Shanghai 10th People's Hospital · Academic / Other
- Sex
- All
- Age
- 35 Years
- Healthy volunteers
- Not accepted
Summary
Uric acid is the final breakdown product of purine degradation in humans. The association between high serum uric acid levels and arterial stiffness as well as endothelial dysfunction has been demonstrated in humans and uric acid has been suggested to be an important modulator of the inflammatory process. But debates still existed for hyperuricemia and hypouricemia as an independent role,especially after controlling other traditional atherosclerotic risk.The aim of this study was, firstly, to verify the association between hyperuricemia and cardiovascular diseases,secondly,to assess whether hypouricemia was an independent risk factor impact for cardiovascular disea.
Detailed description
The study is a longitudinal cohort study. The first cross-sectional survey was conducted in 2011. The eligible participants were followed up from November 2011 to June 2018 (mean follow-up months 68.71±11.35). During the followed-up time, 67 patients had missing data and 56 had no compliance. Thus, the study sample actually comprised 3,047 valid participants (1536 men, 1511 women) whose age older than or equal to 35 years (mean age 60.2±10.4 years) were followed up. A total of hospitalized patients were consecutively enrolled from cardiology department of Beijing and Shanghai. All subjects are under treatment because of cardiovascular diseases.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | antiplatelet drugs ,statins ,antihypertensive drugs | According to the international guidelines, we treated patients who suffered from different disease. |
Timeline
- Start date
- 2011-11-20
- Primary completion
- 2013-03-12
- Completion
- 2018-06-10
- First posted
- 2018-08-06
- Last updated
- 2021-03-24
Source: ClinicalTrials.gov record NCT03616769. Inclusion in this directory is not an endorsement.